Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestogen presented as a 13.5 mg intrauterine system (IUS) for intrauterine use. It provides long‑term hormonal contraception by releasing levonorgestrel locally within the uterus, preventing fertilisation and implantation for up to three years in women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, providing reliable access to this contraceptive device for qualified healthcare providers across multiple regions in the global market.

Jaydess, a levonorgestrel intrauterine system, provides hormonal contraception by acting on the reproductive system.

- Contraception (intrauterine): Provides up to three years of reliable pregnancy prevention for women of reproductive age. - Heavy menstrual bleeding: Reduces menstrual blood loss and may improve cycle regularity in eligible users. - Endometrial protection: Suppresses endometrial proliferation, decreasing the risk of implantation during the device’s active period.

Levonorgestrel IUS may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Headache - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation during insertion - Ectopic pregnancy

Before insertion and during use, certain precautions should be observed to ensure safety and effectiveness.

- Patient selection: Verify absence of active pelvic infection, uterine anomalies, or known pregnancy before insertion. - Contraindications: Do not use in women who are pregnant, have unexplained vaginal bleeding, or have a history of hormone‑dependent malignancies. - Breastfeeding: Discuss potential risks; generally avoid during early postpartum period unless benefits outweigh risks. - Medication review: Assess concomitant drugs that may alter levonorgestrel effectiveness, such as enzyme inducers. - Follow‑up care: Schedule a pelvic examination 4–6 weeks after insertion to confirm device position. - Store at ambient temperature: Keep the IUS in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel IUS may interact with other medicines, requiring attention to avoid reduced efficacy or increased side effects.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): May significantly lower levonorgestrel levels, reducing contraceptive efficacy. - Antifungal azoles (e.g., ketoconazole): Can increase systemic levonorgestrel exposure, raising risk of hormonal side effects. - Antiretroviral agents (e.g., efavirenz): May decrease hormone concentrations and compromise contraceptive protection.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., tetracycline, metronidazole): Potential modest reduction in contraceptive effectiveness; advise backup method. - Herbal supplements (e.g., St. John’s wort): May induce hepatic enzymes and affect hormone levels; monitor clinical response.